Biometrics

Exact Sciences Launches Riskguard™ Hereditary Cancer Test in the United States

Retrieved on: 
Wednesday, February 28, 2024

Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.

Key Points: 
  • Exact Sciences Corp., a leading provider of cancer screening and diagnostic tests, today announced the launch of the Riskguard™ hereditary cancer test in the United States.
  • Offering more effective personalized screening solutions supports Exact Sciences’ commitment to help detect cancer earlier.”
    For patients already diagnosed with cancer, knowing about certain gene variants can help create individualized treatment plans for patients.
  • Exact Sciences’ customer care teams are available to help patients explore the testing process and understand possible results and outcomes.
  • The test is processed in Marshfield, WI at PreventionGenetics, an Exact Sciences laboratory qualified to perform high-complexity clinical laboratory testing that has been providing quality genetic testing since 2004 and joined Exact Sciences in 2022.

Reperio Launches Reperio Pro As Complementary Offering in its Product Roadmap for Next-Generation Biometric Health Screenings

Retrieved on: 
Tuesday, February 27, 2024

Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today the launch of Reperio Professional (Reperio Pro), which now expands the use of the company’s proprietary technology to support a modernized and user-friendly biometric health screening flow.

Key Points: 
  • Reperio Health , the only provider of at-home and onsite comprehensive health screenings with instant results, announced today the launch of Reperio Professional (Reperio Pro), which now expands the use of the company’s proprietary technology to support a modernized and user-friendly biometric health screening flow.
  • The new product is complementary to the self-directed version deployed for at-home biometric health screenings.
  • Reperio Pro offers clinicians and providers access to Reperio’s next-generation mobile app and screening kit for fast and comprehensive biometric health screenings with instant results.
  • With Reperio Pro, we’ve maintained the integrity of the at-home screening flow while developing a complementary iteration for screening professionals out in the field.

Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines

Retrieved on: 
Tuesday, February 27, 2024

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that its Decipher Prostate Genomic Classifier is the only gene expression test to receive a “Level 1B” evidence rating in the 2024 NCCN* Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a prognostic tool for the risk stratification of patients with localized prostate cancer.
  • Level 1B was assigned to Decipher Prostate based on the evidence in both the post-biopsy and post-prostatectomy settings.
  • Additionally, because of this classification, the Decipher Prostate test is the only gene expression test for which the guidelines synthesize the available published data in a separate table that summarizes treatment implications for patients based on both their NCCN risk classification and Decipher score.
  • They summarize the treatment implications for patients based on their Decipher score and the published evidence from analyses of multiple randomized, phase 3 clinical trials.

Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance

Retrieved on: 
Monday, February 26, 2024

Quanterix expects 2023 revenue, gross margin and cash usage to be in line with guidance provided on January 10, 2024.

Key Points: 
  • Quanterix expects 2023 revenue, gross margin and cash usage to be in line with guidance provided on January 10, 2024.
  • Quanterix expects to issue a press release regarding its fourth quarter 2023 and full year 2023 financial results prior to the conference call.
  • In conjunction with this announcement, the Company will host a conference call on February 29, 2024 at 4:30 p.m. E.T.
  • Interested investors can also listen to the live webcast from the Event Details page in the Investors section of the Quanterix website at http://www.quanterix.com .

New Dassault Systèmes Virtual Twin Experience Helps Protect Vulnerable Patients and Educate Caregivers at Saint-Louis Hospital AP-HP in Paris

Retrieved on: 
Tuesday, February 27, 2024

To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.

Key Points: 
  • To create this virtual twin, Dassault Systèmes worked with building blueprints, coupled with a 3D scan of the room made on site using its HomeByMe mobile application to check for any discrepancies.
  • Equipped with this information, Dassault Systèmes developed the augmented reality experience enabling the stakeholders to view the virtual simulations within the real-life setting.
  • “Dassault Systèmes had already worked on projects at other hospitals in Paris and understood our mission to offer the highest level of care.
  • “This incredibly innovative educational experience made our health professionals more aware of respiratory cross-transmission risks in the hospital.

Median Technologies to Participate and Speak at the 2024 European Congress of Radiology (ECR), February 28 – March 3, Vienna, Austria

Retrieved on: 
Monday, February 26, 2024

Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.

Key Points: 
  • Median Technologies (FR0011049824, ALMDT, PEA/SME eligible) announces today that the Company will be participating and speaking at the premier European radiology conference, the European Congress of Radiology (ECR), being held in Vienna, Austria, February 28 – March 3, 2024.
  • Philippe Grenier, Thoracic Radiologist and Head of the Artificial Intelligence project, Foch Hospital, Saint Cloud, France and Pr.
  • The European Congress of Radiology (ECR) organized by the European Society of Radiology (ESR) is the premier European event in radiology and the second largest in the world.
  • The congress conveys more than 20,000 with a split of more than 10,000 professional delegates (radiologists, technologists etc.

Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

Retrieved on: 
Monday, February 26, 2024

These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.

Key Points: 
  • These relationships further the company’s goal to build the global infrastructure necessary for AD testing by expanding clinical access to Quanterix’s leading blood biomarker assays.
  • This reach will provide greater access to patients for high-accuracy, non-invasive AD testing.
  • Traditional AD diagnosis has relied on combination of symptom presentation, brain imaging, and the detection of CSF biomarkers for AD.
  • “In our pursuit to build the global testing infrastructure for Alzheimer’s disease, Quanterix is pleased to work with several health systems whose combined networks treat millions of patients,” said Masoud Toloue, CEO of Quanterix.

Edwards Lifesciences to Present at the 44th Annual TD Cowen Healthcare Conference

Retrieved on: 
Friday, February 23, 2024

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

Key Points: 
  • Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.
  • Bernard Zovighian, chief executive officer, and Scott Ullem, chief financial officer, are scheduled to present at 10:30 a.m.
  • ET.
  • A live webcast of the presentation will be available on the Edwards Lifesciences investor relations website at http://ir.edwards.com/ , with an archived version accessible later the same day.

FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecasts, 2020-2023 and 2024-2034 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 23, 2024

The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering.
  • This report delivers an in-depth understanding of FcRn Inhibitor, addressable patient pool, competitive landscape, and future market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the UK, and Japan.
  • The FcRn Inhibitor market report provides insights around existing treatment practices in patients with FcRn Inhibitor, approved (if any) and emerging FcRn Inhibitor, market share of individual therapies, patient pool eligible for treatment with FcRn Inhibitor, along with current and forecasted 7MM FcRn Inhibitor market size from 2020-2034 by therapies and by indication.
  • This section will include details on changing FcRn Inhibitor market dynamics post initiation of clinical development activities of the inhibitor.

CAP Updates Validation of Immunohistochemical Assays Testing Guideline for Precise Results, Improved Patient Care

Retrieved on: 
Friday, February 23, 2024

The College of American Pathologists (CAP) updated the “Principles of Analytic Validation of Immunohistochemical Assays” guideline to provide increased precision and accuracy of clinical immunohistochemical assays.

Key Points: 
  • The College of American Pathologists (CAP) updated the “Principles of Analytic Validation of Immunohistochemical Assays” guideline to provide increased precision and accuracy of clinical immunohistochemical assays.
  • This update assesses evidence published since the release of the original guideline in 2014 and provides new recommendations on how to analytically validate/verify immunohistochemical assays used for diagnostic and predictive purposes.
  • “This updated guideline provides new and revised recommendations for analytic validation/verification of immunohistochemical assays, which often guide therapeutic decision making for cancer treatment,” explains guideline chair, Jeffrey D. Goldsmith, MD, FCAP.
  • Current tools, resources, and information for the Principles of Analytic Validation of Immunohistochemical Assays: Guideline Update can be found on the guideline webpage on cap.org.